ArticleClinical immunology (Orlando, Fla.)2017
Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
Abstract read
In one paragraph
Article in Clinical immunology (Orlando, Fla.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 74 citations in OpenAlex.
- Review
- Recent advances in the pharmacology of voltage-gated ion channels.Pharmacological reviews · 2025Review
- Limosilactobacillus reuteri enables oral-to-systemic absorption of iberiotoxin for treatment of collagen-induced arthritis in rats.Microbial cell factories · 2025Article
- Anti-inflammatory peptide therapeutics and the role of sulphur containing amino acids (cysteine and methionine) in inflammation suppression: A review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Review
- Kv1.3 blockade by ShK186 modulates CD4+ effector memory T-cell activity of patients with granulomatosis with polyangiitis.Rheumatology (Oxford, England) · 2024Article
- Exploring the therapeutic opportunities of potassium channels for the treatment of rheumatoid arthritis.Frontiers in pharmacology · 2024Review
- Peptides with Diverse Functions from Scorpion Venom: A Great Opportunity for the Treatment of a Wide Variety of Diseases.Iranian biomedical journal · 2023Article
- A bioengineered probiotic for the oral delivery of a peptide Kv1.3 channel blocker to treat rheumatoid arthritis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- The immunosuppressive effects and mechanisms of loureirin B on collagen-induced arthritis in rats.Frontiers in immunology · 2023Article
- Adeno-Associated virus 8 delivers an immunomodulatory peptide to mouse liver more efficiently than to rat liver.PloS one · 2023Article
- Structural Studies of Expressed tIK, Anti-Inflammatory Peptide.International journal of molecular sciences · 2022Article
- How the Potassium Channel Response of T Lymphocytes to the Tumor Microenvironment Shapes Antitumor Immunity.Cancers · 2022Review
- Pharmacological blockade of KV1.3 channel as a promising treatment in autoimmune diseases.Journal of translational autoimmunity · 2022Review
- Discovery of KMedicinal research reviews · 2021Review
- The Kv1.3 KBiologia futura · 2021Review
- Pharmacological Approaches to Studying Potassium Channels.Handbook of experimental pharmacology · 2021Review
- From Animal Poisons and Venoms to Medicines: Achievements, Challenges and Perspectives in Drug Discovery.Frontiers in pharmacology · 2020Review
- Antibodies and venom peptides: new modalities for ion channels.Nature reviews. Drug discovery · 2019Review
- Antiinflammatory peptides: current knowledge and promising prospects.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019Review
- KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis.Arthritis research & therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Mark R TannerDepartment of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX 77030, USA; Interdepartmental Graduate Program in Translational Biology & Molecular Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Rajeev B TajhyaDepartment of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX 77030, USA; Graduate Program in Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX 77030, USA.
Redwan HuqDepartment of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX 77030, USA; Graduate Program in Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX 77030, USA.
Elizabeth J GehrmannDepartment of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX 77030, USA.
Kathia E RodarteDepartment of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX 77030, USA.
Mustafa A AtikDepartment of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Raymond S NortonMedicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Michael W PenningtonPeptides International, 11621 Electron Drive, Louisville, KY 40299, USA.
Christine BeetonDepartment of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX 77030, USA; Biology of Inflammation Center and Center for Drug Discovery, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: beeton@bcm.edu.
Baylor College of Medicine · USMonash University · AUPeptides International (United States) · US
Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9MUM1HG006348: Cas9 Genome Integrity Supplemental ProposalUM1HG006348 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI Jason D. Heaney, Chih-Wei Logan Hsu · 2016 to 2026
$47.5MPhase II of BUILDing SCHOLARSUL1GM118970 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI ALEY, STEPHEN B, BOLAND, THOMAS · 2015 to 2023
$17.9MConsortium for Broad Based Disease Phenotyping of Knockout MiceU54HG006348 · NHGRI · BAYLOR COLLEGE OF MEDICINE · PI BEAUDET, ARTHUR L., PAYLOR, RICHARD E · 2011 to 2015
$17.0MPhase II of BUILDing SCHOLARS - Student Training CoreTL4GM118971 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI ALEY, STEPHEN B, BOLAND, THOMAS · 2015 to 2023
$9.9MMolecular Physiology of the Cardiovascular SystemT32HL007676 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI HAMILTON, SUSAN L · 1989 to 2020
$7.9MPhase II of BUILDing SCHOLARS - Research Enrichment CoreRL5GM118969 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI ALEY, STEPHEN B, BOLAND, THOMAS · 2015 to 2023
$7.4MImmunology Scientist Training ProgramT32AI053831 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI CORRY, DAVID B · 2003 to 2018
$4.2MTraining Program in Translational Biology and Molecular MedicineT32GM088129 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI ROONEY, CLIONA M., VAN DEN VEYVER, IGNATIA B · 2010 to 2019
$3.0MNew Peptides for the Treatment of Multiple SclerosisR01NS073712 · NINDS · BAYLOR COLLEGE OF MEDICINE · PI BEETON, CHRISTINE · 2011 to 2015
$1.8MBD Biosciences Special Order LSRIIS10RR024574 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI LUMPKIN, ELLEN A · 2009 to 2009
$430kTargeting T lymphocyte potassium channels for the treatment of asthma--OLDR56AI084981 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI BEETON, CHRISTINE · 2010 to 2010
$384kNCI NIH HHS P30 CA125123NCRR NIH HHS S10 RR024574NHGRI NIH HHS U54 HG006348NHGRI NIH HHS UM1 HG006348NHLBI NIH HHS T32 HL007676NIAID NIH HHS R56 AI084981NIAID NIH HHS T32 AI053831NIAMS NIH HHS F31 AR069960NIGMS NIH HHS RL5 GM118969NIGMS NIH HHS T32 GM088129NIGMS NIH HHS TL4 GM118971NIGMS NIH HHS UL1 GM118970NINDS NIH HHS R01 NS073712
Abstract
Effector memory T lymphocytes (T
Indexed as
AdultAllergensAnimalsArthritis, ExperimentalArthritis, RheumatoidCell LineCells, CulturedFemaleHumansHypersensitivity, DelayedImmunomodulationKv1.3 Potassium ChannelLeukocytes, MononuclearMiceMiddle AgedOvalbuminAllergensKv1.3 Potassium ChannelOvalbuminPeptidesPolyethylene GlycolsPotassium Channel BlockerspristaneScorpion VenomsTerpenesTX1 toxin, Heterometrus spinniferDisulfide rich peptideEffector memory T lymphocyteImmunomodulationKCNA3PEGylated Kv1.3 blockerVoltage-gated channel
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.